|Day Low/High||158.31 / 161.15|
|52 Wk Low/High||114.27 / 197.00|
We exited one stock, entered another, raised our price target on Kohl's and downgraded Nordstrom.
A healthcare bill supported on both sides of the aisle was held up until Sen. Chuck Grassley talked with pharma companies.
Stocks finished mixed on Thursday as concerns mount over the potential for a major rift on trade and tariffs when G-7 leaders meet later this week.
U.S. stock futures are higher on Thursday and stocks in Europe and Asia extend gains; Jamie Dimon and Warren Buffett urge companies to consider no longer providing quarterly earnings guidance.
As futures point higher, these are the headlines you need to get up to speed during your morning commute.
Tech and retail gains aren't enough to lead markets to new highs.
Jim discusses Constellation Brands, Goldman Sachs and a new position in Salesforce.com.
Jim discusses our decision to exit Allergan, the AAP Bullpen, Apple's upcoming Worldwide Developers Conference and more!
After a lot of patience and disappointment, we are closing our remaining small 'spec' position.
They may not get all the attention, but antibiotic drugs are increasingly important.
Following up on a pledge to accelerate generic drugs into the marketplace to stoke price competition, the agency signals pending reform of the Risk Evaluation and Mitigation Strategy.
Here's what you need to know now for Wednesday, May 30.
Company's plans to sell two small units are largely a cosmetic fix.
The Dublin-based drugmaker has wrapped up a strategic review of all its businesses, but says it's not pursuing a fire sale of its assets.
Aegon announces that it is exercising its right to redeem the EUR 200 million 6% perpetual capital securities.
Jim Cramer weighs in on Royal Caribbean, Allergan, Tyson Foods, Carrizo Oil & Gas, Valeant Pharmaceuticals, Okta, CRISPR Therapeutics and more.
Jim Cramer says the hope that the trade dispute with China can be worked out was the fuel for this rally.
Aimovig is the first treatment approved by the agency to prevent migraines by blocking the calcitonin gene-related peptide receptor.
Here's what you need to know now for Thursday, May 17.
The chief commercial officer's appearance at a Bank of America healthcare conference came a day after Allergan competitor Evolus said it had received a complete response letter regarding its application for Botox rival DWP-450.
Jim discusses Macy's quarter as a readthrough to Nordstrom, defense and North Korea, and more on the market!
The insurgent manager who helped engineer the Amazon-Whole Foods combination opened a window into his latest allocations, any of which could become campaigns. Here's a wrap up of his investments as well as new developments from Mick McGuire's Marcato Capital and Dan Loeb's Third Point.
The markets strongly rebounded this week as a few of the major averages pushed into positive year-to-date territory.
The most recent short interest data has been released for the 04/13/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
The Dublin-based drugmaker will provide communications on the strategic review in 'weeks, not months,' Allergan CFO Matthew Walsh said at the Deutsche Bank healthcare conference.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.